Q-omics provides the consensus-scored PRPF4BP1 profile across patient tissues and cancer cell-line models. PRPF4BP1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PRPF4BP1 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, PRPF4BP1 RNA expression shows 5,739 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight BLCA, LUAD, and OV as cancer lineages where PRPF4BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF4BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF4BP1 survival associations across molecular data types. PRPF4BP1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF4BP1 RNA expression–survival associations across cancer types. High PRPF4BP1 expression shows unfavorable associations in THYM, MESO, CHOL and ACC, but favorable associations in BLCA and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify BLCA as the clearest survival context for PRPF4BP1 RNA expression.
This table summarizes PRPF4BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRPF4BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF4BP1 shows higher tumor expression in LUAD. The LUAD box plot shows higher PRPF4BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .029).
This table shows molecular features associated with PRPF4BP1 in patient tissues and cancer cell lines. In patient samples, PRPF4BP1 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
